Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEART-C: Elbasvir/Grazoprevir in HCV and Metabolic Disease
NCT03585101Phase 4Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of grazoprevir in hepatitis C (HCV), sponsored by University of California, Los Angeles. Primary endpoint: Reactive Hyperemia Index. Planned start Aug 2018; status: withdrawn.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03585101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585101.